Bladder Cancer Clinical Trial
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Summary
The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
Eligibility Criteria
Inclusion Criteria:
Have histologically or cytologically confirmed locally advanced unresectable or metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter, urinary bladder or urethra)
Received 1 or 2 prior treatment regimens for advanced or metastatic disease
Confirmed radiologic disease progression during or following recent treatment
Mandatory biopsy is required during screening
Measurable disease per RECIST v1.1
Adequate organ function
ECOG 0 or 1
Exclusion Criteria:
Prior treatment with a PARP inhibitor
Symptomatic and/or untreated CNS metastases
Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption of rucaparib
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 64 Locations for this study
Scottsdale Arizona, 85258, United States
La Jolla California, 92093, United States
Los Angeles California, 90095, United States
Orange California, 92868, United States
Santa Monica California, 90404, United States
Stanford California, 94304, United States
Hartford Connecticut, 06102, United States
Norwich Connecticut, 06360, United States
Washington District of Columbia, 20007, United States
Miami Florida, 33176, United States
Chicago Illinois, 60611, United States
Indianapolis Indiana, 46202, United States
Iowa City Iowa, 52242, United States
Louisville Kentucky, 40207, United States
New Orleans Louisiana, 70121, United States
Baltimore Maryland, 21201, United States
Ann Arbor Michigan, 48109, United States
Minneapolis Minnesota, 55404, United States
Las Vegas Nevada, 89169, United States
Hackensack New Jersey, 07601, United States
Albuquerque New Mexico, 87102, United States
Albany New York, 12208, United States
Buffalo New York, 14263, United States
New York New York, 10021, United States
New York New York, 10065, United States
Durham North Carolina, 27710, United States
Oklahoma City Oklahoma, 73104, United States
Portland Oregon, 97062, United States
Portland Oregon, 97213, United States
Portland Oregon, 97239, United States
Allentown Pennsylvania, 18103, United States
Hershey Pennsylvania, 17033, United States
Myrtle Beach South Carolina, 29572, United States
Chattanooga Tennessee, 37403, United States
Nashville Tennessee, 37209, United States
Dallas Texas, 76201, United States
Houston Texas, 77030, United States
Salt Lake City Utah, 84112, United States
Charlottesville Virginia, 22908, United States
Seattle Washington, 98109, United States
Milwaukee Wisconsin, 53226, United States
Lyon , 69008, France
Paris , 75010, France
Saint-Herblain , 44805, France
Toulouse , 31059, France
Villejuif , 94805, France
Erlangen , 91054, Germany
Münster , 26133, Germany
Nurtingen , 72622, Germany
Candiolo , 10060, Italy
Milano , 20132, Italy
Milano , 20133, Italy
Naples , 80131, Italy
Pamplona Navarre, 31008, Spain
Barcelona , 08003, Spain
Barcelona , 08025, Spain
Barcelona , 08035, Spain
Madrid , 28007, Spain
Madrid , 28027, Spain
Madrid , 28033, Spain
Madrid , 28041, Spain
Santiago De Compostela , 15706, Spain
London , CH63 , United Kingdom
London , W1G 6, United Kingdom
How clear is this clinincal trial information?